0001601830-24-000179.txt : 20241017 0001601830-24-000179.hdr.sgml : 20241017 20241017172744 ACCESSION NUMBER: 0001601830-24-000179 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20241015 FILED AS OF DATE: 20241017 DATE AS OF CHANGE: 20241017 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Borgeson Blake CENTRAL INDEX KEY: 0001856094 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40323 FILM NUMBER: 241378440 MAIL ADDRESS: STREET 1: C/O RECURSION PHARMACEUTICALS STREET 2: 41 S. RIO GRANDE STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84101 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: RECURSION PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001601830 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 464099738 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 41S RIO GRANDE STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84101 BUSINESS PHONE: (385) 269-0203 MAIL ADDRESS: STREET 1: 41S RIO GRANDE STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84101 FORMER COMPANY: FORMER CONFORMED NAME: Recursion Pharmaceuticals, LLC DATE OF NAME CHANGE: 20140305 4 1 wk-form4_1729200457.xml FORM 4 X0508 4 2024-10-15 0 0001601830 RECURSION PHARMACEUTICALS, INC. RXRX 0001856094 Borgeson Blake C/O RECURSION PHARMACEUTICALS 41 S. RIO GRANDE STREET SALT LAKE CITY UT 84101 1 0 0 0 1 Class A Common Stock 2024-10-15 4 S 0 11447 6.6678 D 7089007 D This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023. This transaction was executed in multiple trades at prices ranging from $6.50 to $6.74. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. /s/Jonathan Golightly, attorney-in-fact 2024-10-17